According to ARRS’ American Journal of Roentgenology (AJR), an AI tool for detection of incidental pulmonary embolus (iPE) on conventional contrast-enhanced chest CT examinations had high NPV and moderate PPV, even finding some iPEs missed by radiologists

Left: Axial image shows central nonocclusive filling defect in right lower lobe lateral subsegmental pulmonary artery (arrow). Examination classified positive for iPE by AI but negative for iPE by clinical report. Adjudication process used for reference standard determination classified examination as positive for iPE. Right: Activation map shows location corresponding with iPE identified by AI (arrow). 


July 21, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), an AI tool for detection of incidental pulmonary embolus (iPE) on conventional contrast-enhanced chest CT examinations had high NPV and moderate PPV, even finding some iPEs missed by radiologists. 

“Potential applications of the AI tool include serving as a second reader to help detect additional iPEs or as a worklist triage tool to allow earlier iPE detection and intervention,” wrote lead investigator Kiran Batra from the University of Texas Southwestern Medical Center in Dallas. “Various explanations of misclassifications by the AI tool (both false positives and false negatives) were identified, to provide targets for model improvement.” 

Batra and colleagues’ retrospective study included 2,555 patients (1,340 women, 1,215 men; mean age, 53.6 years) who underwent 3,003 conventional contrast-enhanced chest CT examinations between September 2019 and February 2020 at Parkland Health in Dallas, TX. Using an FDA-approved, commercially available AI tool (Aidoc, New York, NY) to detect acute iPE on the images, a vendor-supplied natural language processing algorithm (RepScheme, Tel Aviv, Israel) was then applied to the clinical reports to identify examinations interpreted as positive for iPE. 

Ultimately, the commercial AI tool had NPV of 99.8% and PPV of 86.7% for detection of iPE on conventional contrast-enhanced chest CT examinations (i.e., not using CT pulmonary angiography protocols). Of 40 iPEs present in the team’s study sample, 7 were detected only by the clinical reports, and 4 were detected only by AI. 

Noting that both the AI tool and clinical reports detected iPEs missed by the other method, “the diagnostic performance of the AI tool did not show significant variation across study subgroups,” the authors of this AJR article added

For more information: arrs.org 


Related Content

News | Interventional Radiology

May 12, 2026 — Siemens Healthineers has received clearance from the Food and Drug Administration for six new systems in ...

Time May 12, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

May 11, 2026 – At the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE ...

Time May 11, 2026
arrow
News | Radiopharmaceuticals and Tracers

May 7, 2026 — Bayer has announced positive topline results from the Phase III REVEAL study, an investigator-initiated ...

Time May 08, 2026
arrow
News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
News | ASE

May 4, 2026 — The American Society of Echocardiography (ASE) has released a new guideline that provides guidance for ...

Time May 05, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

April 27, 2026 — SimonMed, one of the nation’s largest independent outpatient imaging providers, has announced the ...

Time May 04, 2026
arrow
News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
News | Imaging Software Development

April 28, 2026 — Avatar Medical has been granted FDA 510(k) clearance for Avatar Medical Vision, its software platform ...

Time April 28, 2026
arrow
News | Cardiac Imaging

April 28, 2026 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next ...

Time April 28, 2026
arrow
News | FDA

April 16, 2026 — Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral ...

Time April 20, 2026
arrow
Subscribe Now